Impact of cannabidiol on myocardial recovery in patients with acute myocarditis: Rationale & design of the ARCHER trial.
Dennis M McNamaraLeslie T CooperYaron ArbelArvind BhimarajEdimar BocchiMatthias G FriedrichMatthieu KerneisPeter LiuAndrea B ParkerEldon R SmithW H Wilson TangGuillermo Torre-AmioneCarsten Tschöpenull nullPublished in: ESC heart failure (2024)
The ongoing ARCHER Trial is an international, multicentre, double-blind, randomized, placebo-controlled phase II study, designed to determine the effect of a pharmaceutically produced cannabidiol formulation on CMR parameters in patients presenting with acute myocarditis. Enrolment of 100 patients is expected to conclude in Q3 2024. Study results will be available in early 2025.
Keyphrases
- placebo controlled
- double blind
- phase iii
- phase ii study
- phase ii
- clinical trial
- study protocol
- open label
- end stage renal disease
- chronic kidney disease
- randomized controlled trial
- ejection fraction
- heart failure
- prognostic factors
- health insurance
- squamous cell carcinoma
- locally advanced
- acute respiratory distress syndrome